Abbott Laboratories

  • Market Cap: Large Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0028241000
USD
84.47
-0.43 (-0.51%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Abbott Laboratories stock-summary
stock-summary
Abbott Laboratories
Pharmaceuticals & Biotechnology
Abbott Laboratories (Abbott) is engaged in the discovery, development, manufacture, and sale of a diversified line of health care products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Company focuses on cardiovascular, diabetes care, diagnostics, neuromodulation, nutrition and medicine. It offers products, including FreeStyle, PediaSure, Pedialyte, Similac, EleCare, ZonePerfect, Juven, Ensure and Glucerna. The Company’s products are sold directly to wholesalers, distributors, government agencies, health care facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. The cardiovascular's products include Portico, MitraClip, Dilatation Catheter, among others. The diagnostics products include IntelliFISH, Vysis ALK, STARLIMS, PathVysion, AlinIQ, among others.
Company Coordinates stock-summary
Company Details
100 Abbott Park Rd , ABBOTT PARK IL : 60064-3500
stock-summary
Tel: 1 224 6676100
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 245 Schemes (33.99%)

Foreign Institutions

Held by 643 Foreign Institutions (17.19%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Miles White
Executive Chairman of the Board
Mr. Robert Ford
President, Chief Executive Officer, Director
Mr. William Osborn
Lead Independent Director
Dr. Robert Alpern
Independent Director
Ms. Roxanne Austin
Independent Director
Ms. Sally Blount
Independent Director
Ms. Michelle Kumbier
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
11,164 Million
(Quarterly Results - Mar 2026)
Net Profit:
1,077 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 214,677 Million (Large Cap)

stock-summary
P/E

32.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.10

stock-summary
Return on Equity

0.00%

stock-summary
Price to Book

0.00